Skip to main content

Advertisement

SpringerLink
Log in

T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy

  • Urology – Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Background

The management of stage T1 poorly differentiated G3 bladder cancer invading the lamina propria continues to be debated. These tumours are associated with a high risk of recurrence and progression; concomitant carcinoma in situ and/or multifocality are negative prognostic factors. Choosing between a preserving approach such as trans-urethral resection of the bladder (TURB) followed by maintenance bacillus Calmette-Guerin (BCG) and an invasive approach like cystectomy is critical.

Patients and methods

Overall, 80 patients underwent TURB and RE-TURB followed by intra-vesical induction treatment with BCG plus maintenance (Group A) while 72 patients underwent immediate radical cystectomy with extended lymphadenectomy (Group B). Patients were divided into 3 subgroups: uni-focal tumours, multi-focal tumours and carcinoma in situ associated lesions. In Group A, time to first recurrence and time to progression were analysed. A comparison was made between Group A and Group B regarding progression-free survival, cancer-specific survival and overall survival with a median follow-up time of 8.3 years.

Results

As far as concerns Group A patients, 42 recurrences (52.5%) were reported in a median time of 10.4 months (range 3–26) and 25 progressions (31.2%) in a median time of 25 months (range 3–68). As far as concerns time to first recurrence and time to progression, both the Kaplan–Meier survival curves obtained are significant and P values are, respectively, 0.0263 and 0.0011. Comparing Groups A and B patients, 25 progressions (31.2%) in a median time of 25 months (range 3–68) and 18 progressions (25%) in a median time of 25.9 months (range 4–72), respectively, were recorded. Regarding overall survival, at 10 years, 24 deaths (42.5%) occurred in a median time of 55.4 months (range 12–94) in Group A and 42 deaths (58.3%) in a median time of 54.9 months (10–100) in Group B. Cancer-specific survival was evaluated in Group A with a total of 18 deaths (22.5%) in a median time of 47.5 months (range 16–78), and in Group B with a total of 16 deaths (22.2%) in a median time of 45.7 months (range 16–88). The progression-free survival Kaplan–Meier curve is not significant, the P value being 0.3801; the overall survival curve is significant with a P value of 0.0487 while the cancer-specific survival curve is not significant with a P value of 0.9762.

Discussion

In Group A, considering “time to first recurrence”, the difference is greater between unifocal lesions and multifocal or Cis-associated lesions. Conversely, for “time to progression”, there is a greater difference between unifocal and multifocal tumours and Cis-associated tumours. Looking at “progression-free survival” in Group A and Group B patients, there is no statistically significant difference, like in cancer-specific survival. A statistically significant difference was observed in overall survival being in favour of conservative treatment thus reflecting that conservative treatment is not burdened by all the surgical and post-operative complications of cystectomy.

Conclusions

Although NMIBC invading the lamina propria, stage G3, with or without Cis-associated lesions are burdened both by a high volume of recurrences and progressions, cystectomy could be considered an aggressive approach. New biological markers are now needed which are able to predict the behaviour of the cancer and to guide the decision-making process between conservative or aggressive treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ro JY, Ayala AG, el-Naggar A (1987) Muscularis mucosa of urinary bladder. Importance for staging and treatment. Am J Surg Pathol 11:668–673

    Article  PubMed  CAS  Google Scholar 

  2. van Rhijn BWB, Burger M, Lotan Y et al (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56:430–442

    Article  PubMed  Google Scholar 

  3. Thalmann GN, Markwalder R, Studer UE et al (2004) Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 172:70–75

    Article  PubMed  Google Scholar 

  4. Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA et al (2006) Predicting recurrence, progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from 7 EORTC trials. Eur Urol 49:466–477

    Article  PubMed  Google Scholar 

  5. Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ, Dalbagni G (2007) Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177(4):1283–1286

    Article  PubMed  Google Scholar 

  6. Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964–1970

    Article  PubMed  CAS  Google Scholar 

  7. Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD (2004) Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93:485–490

    Article  PubMed  CAS  Google Scholar 

  8. Witjes JA (2004) Bladder carcinoma in situ in 2003: state of the art. Eur Urol 45(2):142–146

    Article  PubMed  CAS  Google Scholar 

  9. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649–655

    Article  PubMed  CAS  Google Scholar 

  10. Volkmer BG, Kuefer R, Bartsch C, Gust K, Hautmann RE (2009) Oncological followup after radical cystectomy for bladder cancer-is there any benefit? J Urol 181:1587–1593

    Article  PubMed  Google Scholar 

  11. Babjuk M (2010) What is the optimal treatment strategy fo T1 bladder tumors? Eur Urol 57:32–34

    Article  PubMed  Google Scholar 

  12. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou J, Roupret M (2010) European Association of Urology Guidelines

  13. Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M (2000) Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev 4:CD001986

    Google Scholar 

  14. Bohle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90–95

    Article  PubMed  CAS  Google Scholar 

  15. Lundholm C, Norlén BJ, Ekman P, Jahnson S, Lagerkvist M, Lindeborg T et al (1996) A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 156:372

    Article  PubMed  CAS  Google Scholar 

  16. de Reijke TM, Kurth KH, Sylvester RJ et al (2005) Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906). J Urol 173(2):405–409

    Article  PubMed  Google Scholar 

  17. Bohle A, Bock PR (2004) Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63:682–686

    Article  PubMed  CAS  Google Scholar 

  18. Lamm DL, Blumenstein DA, Crissman JD et al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163:1124–1129

    Article  PubMed  CAS  Google Scholar 

  19. van Der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV (2003) Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44(4):429–434

    Article  PubMed  Google Scholar 

  20. Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat A, Zlotta A (2010) An update critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previosly T1G3) bladder cancer. Eur Urol 57:60–70

    Article  PubMed  Google Scholar 

  21. Dalbagni G, Herr HW, Reuter VE (2002) Impact of second transurethral resection on the staging of T1 bladder cancer. Urology 60:822–824

    Article  PubMed  Google Scholar 

  22. Stein JP, Cai J, Groshen S, Skinner DG (2003) Risk factors for patients with pelvic lymph node metastses following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol 170:35–41

    Article  PubMed  Google Scholar 

  23. Stein JP, Lieskovsky G, Cote R, Groshen S et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 19:666–675

    PubMed  CAS  Google Scholar 

  24. Kulkarni GS, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Alibhai SM (2007) Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med 4:e284

    Article  PubMed  Google Scholar 

  25. Hautmann RE, Volkmer BG, Gust K (2009) Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1G3). World J Urol 27(3):347–351

    Article  PubMed  Google Scholar 

  26. Gazzaniga P, Gradilone A, De Berardinis E, Sciarra A et al (2009) A chemosensitivity test to individualize intravesical treatment for non-muscle invasive bladder cancer. BJU Int 104(2):184–188

    Article  PubMed  CAS  Google Scholar 

  27. Canesin G, Gonzalez-Peramato P, Palou J, Urrutia M et al. (2010) Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 31(4):277–285

    Google Scholar 

  28. Gradilone A, Petracca A, Nicolazzo C, Gianni W, Cortesi E et al. (2010) Prognostic significance of surviving-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int 106(5):710–715

    Google Scholar 

  29. Gattegno B (2004) T1G3 bladder cancer: conservative management or cystectomy? Eur Urol 45:399–400

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Sapienza University of Rome, Rome, Italy

    E. De Berardinis, G. M. Busetto, G. Antonini, R. Giovannone & V. Gentile

Authors
  1. E. De Berardinis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. M. Busetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Antonini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Giovannone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Gentile
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. De Berardinis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Berardinis, E., Busetto, G.M., Antonini, G. et al. T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy. Int Urol Nephrol 43, 1047–1057 (2011). https://doi.org/10.1007/s11255-011-9941-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-011-9941-x

Keywords

Search

Navigation